The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Anacetrapib; Atorvastatin; Atorvastatin Calcium; Oxazolidinones

Criteria

Inclusion Criteria:

• Patient's weight has been stable for at least 6 weeks

• Patient is in good health based on medical history, physical exam, and laboratory tests

• Patient has dyslipidemia

Exclusion Criteria :

• Patient has a history of stroke, seizures, or major neurological disorders

• Patient has a history of cancer

• Patient is currently taking any lipid-lowering medications or substances except for statins

• Patient consumes excessive amounts of alcohol or caffeine

• Patient has multiple and/or severe allergies to food or drugs